We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Highlights Comprehensive Portfolio of New Assays at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: The HbA1c net FS uses a new enzymatic method for the determination of HbA1c (Photo courtesy of DiaSys)
Image: The HbA1c net FS uses a new enzymatic method for the determination of HbA1c (Photo courtesy of DiaSys)

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is showcasing its new products, including its latest immunoturbidimetric test for the determination of procalcitonin, at Medlab Middle East 2023.

At this year’s Medlab Middle East, DiaSys is presenting its latest reagents HDL-c direct FS, LDL-c direct FS, Cystatin C FS, Procalcitonin FS and CRP FS. The company’s innovative new reagents, HDL-c direct FS and LDL-c direct FS, are homogenous assays for direct determination of high-density lipoproteins (HDL) and low-density lipoproteins (LDL). The high quality reagents offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

DiaSys is showcasing the Cystatin C FS, an immunturbidemetric assay that can be applied on a broad range of clinical chemistry analyzers. The assay is characterized by an outstanding analytical sensitivity in addition to superior correlation with nephelometry. It has excellent onboard and calibration stabilities up to 12 weeks and a high prozone security. The standardized test is essential for reliable kidney diagnosis of clinical-chemistry laboratories. DiaSys is also highlighting the Procalcitonin FS, a fluid-stable, particle enhanced immunoturbidimetric assay with outstanding onboard and calibration stability that provides a convenient workflow on clinical chemistry analyzers. Determinations of PCT in serum and plasma within the measuring range from 0.2 ng/mL to 50 ng/mL can be performed with high precision at clinical cut-off levels for sepsis. The performance is complemented by high tolerance to endogenous interferents and various therapeutics used in sepsis management. Procalcitonin FS shows a good correlation to established methods. Results from ring trials and a publication demonstrate the strengths of the assay.

In addition, DiaSys is highlighting the CRP FS liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls. The test results are fully quantitative which allows true differentiation of borderline cases. The test is standardized to the international reference material, has a wide measuring range, high prozone security and excellent correlation to competitor tests. The test is easily applicable to clinical chemistry analyzers with a variety of instrument applications available.

Related Links:
DiaSys Diagnostic Systems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.